We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Hologic (HOLX) Beats Stock Market Upswing: What Investors Need to Know
Read MoreHide Full Article
Hologic (HOLX - Free Report) closed at $61.82 in the latest trading session, marking a +1.83% move from the prior day. The stock's performance was ahead of the S&P 500's daily gain of 0.64%. Meanwhile, the Dow gained 0.85%, and the Nasdaq, a tech-heavy index, added 0.31%.
The medical device maker's shares have seen a decrease of 4% over the last month, not keeping up with the Medical sector's loss of 0.88% and outstripping the S&P 500's loss of 7.69%.
Analysts and investors alike will be keeping a close eye on the performance of Hologic in its upcoming earnings disclosure. It is anticipated that the company will report an EPS of $1.02, marking a 0.97% fall compared to the same quarter of the previous year. Our most recent consensus estimate is calling for quarterly revenue of $1 billion, down 1.56% from the year-ago period.
HOLX's full-year Zacks Consensus Estimates are calling for earnings of $4.28 per share and revenue of $4.08 billion. These results would represent year-over-year changes of +4.9% and +1.32%, respectively.
Any recent changes to analyst estimates for Hologic should also be noted by investors. Recent revisions tend to reflect the latest near-term business trends. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the company's business health and profitability.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. Within the past 30 days, our consensus EPS projection has moved 0.05% lower. Hologic is holding a Zacks Rank of #3 (Hold) right now.
In terms of valuation, Hologic is currently trading at a Forward P/E ratio of 14.2. This expresses a discount compared to the average Forward P/E of 27.85 of its industry.
Meanwhile, HOLX's PEG ratio is currently 2.02. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. Medical - Instruments stocks are, on average, holding a PEG ratio of 2.43 based on yesterday's closing prices.
The Medical - Instruments industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 120, positioning it in the top 48% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Hologic (HOLX) Beats Stock Market Upswing: What Investors Need to Know
Hologic (HOLX - Free Report) closed at $61.82 in the latest trading session, marking a +1.83% move from the prior day. The stock's performance was ahead of the S&P 500's daily gain of 0.64%. Meanwhile, the Dow gained 0.85%, and the Nasdaq, a tech-heavy index, added 0.31%.
The medical device maker's shares have seen a decrease of 4% over the last month, not keeping up with the Medical sector's loss of 0.88% and outstripping the S&P 500's loss of 7.69%.
Analysts and investors alike will be keeping a close eye on the performance of Hologic in its upcoming earnings disclosure. It is anticipated that the company will report an EPS of $1.02, marking a 0.97% fall compared to the same quarter of the previous year. Our most recent consensus estimate is calling for quarterly revenue of $1 billion, down 1.56% from the year-ago period.
HOLX's full-year Zacks Consensus Estimates are calling for earnings of $4.28 per share and revenue of $4.08 billion. These results would represent year-over-year changes of +4.9% and +1.32%, respectively.
Any recent changes to analyst estimates for Hologic should also be noted by investors. Recent revisions tend to reflect the latest near-term business trends. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the company's business health and profitability.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. Within the past 30 days, our consensus EPS projection has moved 0.05% lower. Hologic is holding a Zacks Rank of #3 (Hold) right now.
In terms of valuation, Hologic is currently trading at a Forward P/E ratio of 14.2. This expresses a discount compared to the average Forward P/E of 27.85 of its industry.
Meanwhile, HOLX's PEG ratio is currently 2.02. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. Medical - Instruments stocks are, on average, holding a PEG ratio of 2.43 based on yesterday's closing prices.
The Medical - Instruments industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 120, positioning it in the top 48% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.